<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02613039</url>
  </required_header>
  <id_info>
    <org_study_id>ANDRO-AOUC-2015-2</org_study_id>
    <nct_id>NCT02613039</nct_id>
  </id_info>
  <brief_title>Oral Contraceptive Therapy and Sexuality</brief_title>
  <acronym>COSEX</acronym>
  <official_title>Study on the Effect of Combined Oral Contraceptive Therapy on Female Sexuality, Body Image and Mental Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florence</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florence</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oral contraceptives (OCs) ameliorate hyperandrogenism and regulate menstrual cycles. To
      reduce androgenic side effects of first- and second-generation progestins, several new
      progestins derived from progesterone or spironolactone have been developed in the last few
      decades. These progestins, such as drospirenone, cyproterone acetate and NOMAC, are designed
      to bind specifically to the progesterone receptor and to have no androgenic, estrogenic or
      glucocorticoid actions.

      However, OCs with a more pronounced anti-androgenic effects are more likely to induce sexual
      dysfunction, mainly hypoactive sexual desire disorder, which can highly impact patient and
      partner's quality of life. Moreover, available data indicate that OC use might increase
      adiposity in adolescents and might be associated with central redistribution of body fat in
      young women with Polycystic ovary syndrome (PCOS) without a recognizable difference in
      clinical anthropometric measurements, including body mass index and waist circumference.

      In this context, it would be worth to evaluate the effects of combined OCs on metabolic and
      sexual health (sexual desire, arousal, and other parameters of sexual health), body image and
      mood.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary study objective Evaluation, in a sample of female outpatient subjects, of the effect
      of oral contraceptives (OCs) on sexual function and distress, evaluated with the FSFI (Female
      Sexual Function Index) and FSDS (Female Sexual Distress Scale Revised) questionnaires and
      through clitoris artery hemodynamic parameters.

      Secondary study objectives

      Evaluation, in a sample of female outpatient subjects, of the effect of OCs on:

        -  body image perception, evaluated with the BUT (Body Uneasiness Test) questionnaire;

        -  mood and mental status, evaluated with the MHQ (Middlesex Hospital questionnaire);

        -  hormonal and metabolic parameters.

      Exploratory Objectives: evaluation of the relationships between hormonal parameters, clinical
      scores and sexual function, body image, mood in the study population.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in sexual function (FSFI score)</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>A significant difference in FSFI score evaluated at baseline compared with follow-up visits will be considered as a primary endpoint.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in sexual distress (FSDS score)</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>A significant difference in FSDS score evaluated at baseline compared with follow-up visits will be considered as a primary endpoint.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in clitoris vascularization</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>A significant difference in clitoris artery hemodynamic parameters evaluated at baseline compared with follow-up visits will be considered as a primary endpoint.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in body image perception</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>A significant difference in BUT score evaluated at baseline compared with follow-up visits will be considered as a primary endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in mood and mental status</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>A significant difference in MHQ score evaluated at baseline compared with follow-up visits will be considered as a primary endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in glycaemia</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>A significant difference in glycaemia levels evaluated at baseline visit and at follow-up visits (6 or 12 months) will be considered as a secondary endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in glycated hemoglobin (HbA1c) levels</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>A significant difference in HbA1c levels evaluated at baseline visit and at follow-up visits (6 or 12 months) will be considered as a secondary endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in insulin levels</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>A significant difference in insulin levels evaluated at baseline visit and at follow-up visits (6 or 12 months) will be considered as a secondary endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in total cholesterol levels</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>A significant difference in total cholesterol levels evaluated at baseline visit and at follow-up visits (6 or 12 months) will be considered as a secondary endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in HDL (high-density lipoprotein) cholesterol levels</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>A significant difference in HDL cholesterol levels evaluated at baseline visit and at follow-up visits (6 or 12 months) will be considered as a secondary endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in triglycerides levels</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>A significant difference in triglycerides levels evaluated at baseline visit and at follow-up visits (6 or 12 months) will be considered as a secondary endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in total testosterone levels</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>A significant difference in total testosterone levels evaluated at baseline visit and at follow-up visits (6 or 12 months) will be considered as a secondary endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in estradiol levels</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>A significant difference in estradiol levels evaluated at baseline visit and at follow-up visits (6 or 12 months) will be considered as a secondary endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in SHBG (sex hormone binding globulin) levels</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>A significant difference in SHBG levels evaluated at baseline visit and at follow-up visits (6 or 12 months) will be considered as a secondary endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in LH (luteinizing hormone) levels</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>A significant difference in LH levels evaluated at baseline visit and at follow-up visits (6 or 12 months) will be considered as a secondary endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in FSH (follicle-stimulating hormone) levels</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>A significant difference in FSH levels evaluated at baseline visit and at follow-up visits (6 or 12 months) will be considered as a secondary endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in prolactin levels</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>A significant difference in prolactin levels evaluated at baseline visit and at follow-up visits (6 or 12 months) will be considered as a secondary endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in delta4-androstenedione levels</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>A significant difference in delta4-androstenedione levels evaluated at baseline visit and at follow-up visits (6 or 12 months) will be considered as a secondary endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Dehydroepiandrosterone sulfate (DHEAS) levels</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>A significant difference in DHEAS levels evaluated at baseline visit and at follow-up visits (6 or 12 months) will be considered as a secondary endpoint.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Contraceptive Usage</condition>
  <condition>Sexual Behavior</condition>
  <condition>Mental Health Wellness 1</condition>
  <arm_group>
    <arm_group_label>female outpatient subjects</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients requiring combined Oral Contraceptives therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combined Estrogen-Progestin Oral Contraceptives</intervention_name>
    <description>All patients enrolled will undergo Combined Estrogen-Progestin Oral Contraceptives. Different compounds will be chosen according to the approved indications and clinical practice. Therefore it is not possible to provide a specific trade and/or generic name.</description>
    <arm_group_label>female outpatient subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subjects aged =/&gt; 18 years and of reproductive age.

          -  Capacity to give consent for study participation, after being adequately informed of
             the aims, benefits, risks, time and motion of the study.

        Exclusion Criteria:

          -  Participation in another clinical trial.

          -  Known or suspected (or history of) malignancy or chronic illness.

          -  Serious organic or mental disease diagnosed by a psychiatrist (e.g., major depression
             currently treated with antidepressant medication) suspected on the basis of the
             medical history and/or clinical examination.

          -  Conditions that may affect the compliance to the study.

          -  Contraindications to therapy with the study drug or hypersensitivity to the study drug
             (active ingredient or excipients of the formulation).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Maggi</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florence</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maro Maggi</last_name>
    <email>m.maggi@dfc.unifi.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Linda Vignozzi</last_name>
    <email>l.vignozzi@dfc.unifi.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ambulatori di Medicina della Sessualit√† e Andrologia</name>
      <address>
        <city>Florence</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Maggi</last_name>
      <email>m.maggi@dfc.unifi.it</email>
    </contact>
    <investigator>
      <last_name>Linda Vignozzi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisa Maseroli</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Egidia Fanni</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Battaglia C, Battaglia B, Mancini F, Nappi RE, Paradisi R, Venturoli S. Moderate alcohol intake, genital vascularization, and sexuality in young, healthy, eumenorrheic women. A pilot study. J Sex Med. 2011 Aug;8(8):2334-43. doi: 10.1111/j.1743-6109.2011.02310.x. Epub 2011 May 19.</citation>
    <PMID>21595833</PMID>
  </reference>
  <reference>
    <citation>Battaglia C, Nappi RE, Mancini F, Cianciosi A, Persico N, Busacchi P, Facchinetti F, de Aloysio D. Menstrual cycle-related morphometric and vascular modifications of the clitoris. J Sex Med. 2008 Dec;5(12):2853-61. doi: 10.1111/j.1743-6109.2008.00972.x. Epub 2008 Aug 28.</citation>
    <PMID>18761595</PMID>
  </reference>
  <reference>
    <citation>Bullivant SB, Sellergren SA, Stern K, Spencer NA, Jacob S, Mennella JA, McClintock MK. Women's sexual experience during the menstrual cycle: identification of the sexual phase by noninvasive measurement of luteinizing hormone. J Sex Res. 2004 Feb;41(1):82-93.</citation>
    <PMID>15216427</PMID>
  </reference>
  <reference>
    <citation>Wierman ME, Nappi RE, Avis N, Davis SR, Labrie F, Rosner W, Shifren JL. Endocrine aspects of women's sexual function. J Sex Med. 2010 Jan;7(1 Pt 2):561-85. doi: 10.1111/j.1743-6109.2009.01629.x. Review.</citation>
    <PMID>20092453</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2015</study_first_submitted>
  <study_first_submitted_qc>November 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2015</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Florence</investigator_affiliation>
    <investigator_full_name>Mario Maggi</investigator_full_name>
    <investigator_title>Full professor of Endocrinology</investigator_title>
  </responsible_party>
  <keyword>oral contraceptives</keyword>
  <keyword>female sexuality</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Contraceptives, Oral, Combined</mesh_term>
    <mesh_term>Progestins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

